Redefining the Standards of Cancer Therapy Research

Albert is a highly accomplished business leader with a deep knowledge of delivering and advising on global operations across the healthcare sector.

Strategically focused, his strengths lie in delivering significant quantifiable and often transformational improvements, restructuring operations and developing and engaging high-calibre personnel to ensure continuous growth, competitive superiority, and profit maximisation.

Albert brings extensive experience to Carcinotech, having served as Director of Global Orthopaedics at Stryker and Managing Director at Orthofix.

Albert is a mentor and advisor to early-stage MedTech and life sciences companies, and collaborates with support organizations such as Scottish Enterprise, Scottish Edge, and EIE.

Ian is a seasoned leader with over 35 years of experience in project, line, and matrix management within the pharmaceutical industry.

With a broad expertise spanning all stages of modern drug discovery, Ian has successfully managed and inspired large discovery-focused teams in both cardiovascular and oncology research at AstraZeneca.

In a unique academic setting, Ian led a team that secured licensing deals with prominent organizations, including 6th Element Capital, AstraZeneca, GSK, IDEAYA, and HitGen.

Ian also brings extensive experience from the CRO environment, having served as Chief Scientific Officer for early discovery at Charles River Laboratories, based at Chesterford Research Park. Simultaneously, he held the role of Executive Director of Biology, leading a global team of over 350 biologists across five sites in three countries.

Lorna is the Chief Scientific Officer of Emulate, a leading Organ-Chip US-based biotechnology company. In this role, she provides strategic guidance and oversight of the scientific vision, partners with government agencies to achieve regulatory acceptance, and collaborates with key customers to advance adoption of organ-on-a-chip technology.

Prior to Emulate, she spent 20 years at AstraZeneca, where she successfully established and led the Microphysiological Systems Centre of Excellence within the R&D Biopharmaceuticals Unit. During her AstraZeneca tenure, Lorna worked within multidisciplinary teams, rotating through different roles and of increasing responsibility in discovery bioscience and safety assessment, spanning target identification through to candidate drug nomination. Lorna’s education is anchored in pharmacology, receiving her PhD from Queen Mary University of London and her undergraduate degree from Aberdeen University.

Susanne is a highly accomplished Finance and Operations executive, bringing over 25 years of commercial industry experience, as well as management, board, and leadership capabilities. A Chartered Accountant, Susanne qualified with PwC and was a Director in the Deals and Restructuring team for 17 years, both in Scotland and London. She has a broad expertise spanning M&A, Restructuring, Fundraising, and Strategic growth across a variety of sectors and multiple stakeholders, including private equity houses, banks, pension funds, and management teams. Susanne has a unique background of leading fundraising and transactions as an advisor at PwC, as well as leading change as a CFO, most recently Group CFO at Anderson Strathern for 6 years. Susanne also brings extensive risk and corporate governance experience, and in previous roles she has been an Executive Board member, Finance Committee member and Risk Committee member and was also on the ICAS Ethics Board for 5 years.

Professor John Connelly leads a multidisciplinary research group focused on the development of next-generation in vitro skin models, and the role of biomechanical cues in skin homeostasis, ageing, and repair at Queen Mary University of London. John has over 20 years experience in the Bioengineering field.

Professor Andrew Biankin is the Regius Chair of Surgery at the University of Glasgow, a Cancer Research UK Clinician Scientist, a Wellcome Trust Senior Investigator, and a Fellow of both the Royal Society of Edinburgh and the Academy of Medical Sciences. He is the Director of the Wolfson Wohl Cancer Research Centre, which focuses on precision oncology, and he established and directs the Glasgow Precision Oncology Laboratory. He holds leadership roles in national and international consortia for cancer genomics and therapeutic development, including serving as Chair of Precision-Panc and Executive Director of the International Cancer Genome Consortium. He has authored over 200 articles in major journals, including seminal works on cancer, genomics, and precision medicine.